Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH)

Author Information

Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi.

Corresponding author:

Dr. Oliech J.S., P.O Box 30197-00100, Nairobi. E-mail:


Background: The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns. Apha blockers and 5 alpha reductase inhibitors address these to variable extents. This article reviews the current place of medical therapy in the treatment of BPH, with a focus on combination therapy.

Data Source: A medline literature search was performed to identify original studies including global multi-center trials and reviews on the subject.

Conclusion: BPH symptom reduction and shrinkage of prostate size by the use of a combination of alpha adrenergic uroselective blocker (Tamsulosin) and 5 alpha iso-enzyme inhibitor (Dutasteride) is a first option of therapy in the management of BPH especially in those cases that are surgical risks with the category of mild to moderate prostate symptom scores.


The Annals of African Surgery is the official publication of the Surgical Society of Kenya.


All content copyright © 2021 Annals of African Surgery.

ISSN (print): 1999-9674; ISSN (online): 2523-0816

Main Office Location: Menelik Medical Centre, Menelik Road, off Ngong Road, Nairobi. First floor.

Telephone: +254715260499



The content on this site is intended for health professionals. Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.

Click here to subscribe and get the latest from Annals of African Surgery

Click here to apply as a Journal Reviewer!

  • Twitter
  • Facebook Social Icon
  • YouTube
  • LinkedIn
  • Instagram